Edwards Lifesciences Corporation (EW)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for EW is $99.77, 15.2% above the last close of $86.60 on Oct 16, 2026; targets range from $89.27 to $110.85. Rating consensus: Buy.
Snapshot
- P/E49.8x
- P/E vs sector+76.8%
- P/E vs own+14.0%
- Target upside+15.2%
- ConsensusBuy
- Market cap$49.9B
- FCF yield+2.9%
- Insiders-$4.54M
- Earnings in19d
- News
Why it moved
Edwards Lifesciences Corporation (EW) fell 1.7% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
1 story on the day (30-day average 0.3).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $86.60 · +19.2% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▼ 100▼ 200▲
- Above MAs2 of 4 above
- MA20×50—
- RSI49
- Support-1.3%
- Resistance+3.4%
- Off 52w high-9.0%
- Off ATH-33.7%
- 52w range$86.60
- Bollingerupper half
- MACD0.22
- ATR+2.5%
- Volume1.1x
Analyst price targets
18 firms with a target in the last 12 months · last close $86.60 · as of Oct 16, 2026
Strong buy 5 · Buy 18 · Hold 7 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +13.6% year over year, free cash flow 33.6% of revenue, operating margin 29.8%.
| Q2 FY2026 | Jun 30, 2026 | $1.74B | 0.42 | $585M | 77.6% | 29.8% | 13.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.65B | 0.66 | -$21.1M | 78.2% | 31.2% | 23.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.57B | 0.16 | $354M | 78.3% | 23.6% | 5.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.55B | 0.50 | $516M | 77.9% | 27.4% | 18.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.53B | 0.56 | $241M | 77.6% | 28.1% | 21.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.41B | 0.61 | $224M | 78.7% | 27.9% | 25.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.39B | 0.65 | -$177M | 78.9% | 22.6% | 27.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.35B | 5.13 | $320M | 80.6% | 25.9% | 226.7% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $104.89 | +0.2% | -17.7% | +16.6% | 33.7 | $181B | |
| 2 |  | $94.75 | -0.7% | -7.1% | +4.0% | 23.3 | $121B | |
| 3 |  | $294.66 | +0.5% | -23.3% | +23.9% | 30.5 | $113B | |
| 4 |  | $44.39 | +0.6% | -57.7% | +50.1% | 18.0 | $64.33B | |
| 5 | | $86.60 | -1.7% | -9.0% | +15.2% | 49.8 | $49.9B | |
| 6 |  | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 7 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 8 |  | $94.98 | +0.6% | -7.7% | +9.0% | 23.1 | $18.12B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.